Decrease in FEV1 and FVC with sodium morrhuate esophageal sclerotherapy.
D000328:Adult; D005227:Fatty Acids / Q000009:adverse effects*; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D012131:Respiratory Insufficiency / Q000209:etiology*; D012976:Sodium Morrhuate / Q000009:adverse effects*; D014797:Vital Capacity
D005227:Fatty Acids; D012976:Sodium Morrhuate